Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis

被引:24
作者
Valadares, Diogo G. [2 ]
Duarte, Mariana C.
Ramirez, Laura [3 ]
Chavez-Fumagalli, Miguel A. [5 ]
Martins, Vivian T. [2 ]
Costa, Lourena E. [4 ]
Lage, Paula S. [4 ]
Ribeiro, Tatiana G. [6 ]
Castilho, Rachel O. [7 ]
Fernandes, Ana Paula [8 ]
Regis, Wiliam C. B. [9 ,10 ]
Soto, Manuel [3 ]
Tavares, Carlos A. P. [2 ]
Coelho, Eduardo A. F. [1 ,4 ]
机构
[1] Univ Fed Minas Gerais, Lab Biotecnol Aplicada Estudo Leishmanioses, Dept Patol Clin, COLTEC, BR-31270901 Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil
[3] Univ Autonoma Madrid, Dept Biol Mol, CSIC UAM, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
[4] Univ Fed Minas Gerais, Fac Med, Programa Posgrad Ciencias Saude Infectol & Med Tr, BR-31270901 Belo Horizonte, MG, Brazil
[5] Univ Fed Minas Gerais, Programa Posgrad Med Mol, BR-31270901 Belo Horizonte, MG, Brazil
[6] Univ Fed Minas Gerais, Programa Posgrad Ciencias Farmaceut, Fac Farm, BR-31270901 Belo Horizonte, MG, Brazil
[7] Univ Fed Minas Gerais, Dept Prod Farmaceut, Fac Farm, BR-31270901 Belo Horizonte, MG, Brazil
[8] Univ Fed Minas Gerais, Dept Anal Clin & Toxicol, Fac Farm, BR-31270901 Belo Horizonte, MG, Brazil
[9] Minasfungi Brasil Ltda, Belo Horizonte, MG, Brazil
[10] Pontificia Univ Catolica Minas Gerais, Belo Horizonte, MG, Brazil
关键词
Visceral leishmaniasis; Agaricus Blazei Murill; Purified fractions; Chemo-prophylaxis; Oral treatment; BALB/c mice; ANTILEISHMANIAL ACTIVITY; IMMUNE-RESPONSES; BETA-GLUCANS; EXTRACT; INFECTION; PAROMOMYCIN; STRATEGIES; DELIVERY;
D O I
10.1016/j.exppara.2012.07.005
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
The present study aimed to investigate the in vitro antileishmanial activity of five fractions obtained from Agaricus blazei water extract (AbM), namely, Fab1, Fab2, Fab3, Fab4, and Fab5; and use the selected leishmanicidal fraction to treat BALB/c mice infected with Leishmania chagasi. A curve dose-titration was performed to obtain the concentration to be test in infected animals. In this context, Fab5 fraction and AbM were used in the doses of 20 and 100 mg/kg/day, respectively, with the product been administered once a day. The effect induced by a chemo-prophylactic regimen, based on the administration Fab5 fraction and AbM 5 days before infection, and maintained for an additional 20 days post-infection was compared to a therapeutic regimen, in which the compounds were administered from 0 to 20 days of infection. Control animals were either treated with amphotericin B deoxycholate (AmpB) or received distilled water. All groups were followed up for 10 weeks post-infection, when parasitological and immunological parameters were analyzed. The Fab5 presented the best results of in vitro leishmanicidal activity. In the in vivo experiments, the use of Fab5 or AbM, as compared to control groups, resulted in significant reduced parasite burdens in the liver, spleen, and draining lymph nodes of the infected animals, as compared to control groups.
引用
收藏
页码:228 / 236
页数:9
相关论文
共 37 条
[1]   Reductions in Skin and Systemic Parasite Burdens as a Combined Effect of Topical Paromomycin and Oral Miltefosine Treatment of Mice Experimentally Infected with Leishmania (Leishmania) amazonensis [J].
Aguiar, Marta Gontijo ;
Machado Pereira, Aline Marcia ;
Fernandes, Ana Paula ;
Miranda Ferreira, Lucas Antonio .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (11) :4699-4704
[2]   Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13 [J].
Basu, Raiatava ;
Bhaumik, Suniti ;
Haldar, Arun Kumar ;
Naskar, Kshudiram ;
De, Tripti ;
Dana, Syamal Kumar ;
Walden, Peter ;
Roy, Syamal .
INFECTION AND IMMUNITY, 2007, 75 (12) :5956-5966
[3]   Clinical status of agents being developed for leishmaniasis [J].
Berman, J .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (11) :1337-1346
[4]   An extract of the mushroom Agaricus blazei Murill administered orally protects against systemic Streptococcus pneumoniae infection in mice [J].
Bernardshaw, S ;
Johnson, E ;
Hetland, G .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2005, 62 (04) :393-398
[5]   Effect of an extract of the mushroom Agaricus blazei Murill on expression of adhesion molecules and production of reactive oxygen species in monocytes and granulocytes in human whole blood ex vivo [J].
Bernardshaw, Soosaipillai ;
Lyberg, Torstein ;
Hetland, Geir ;
Johnson, Egil .
APMIS, 2007, 115 (06) :719-725
[6]   An extract of the medicinal mushroom Agaricus blazei Murill differentially stimulates production of pro-inflammatory cytokines in human monocytes and human vein endothelial cells in vitro [J].
Bernardshaw, Soosaipillai ;
Hetland, Geir ;
Ellertsen, Linda Kathrine ;
Tryggestad, Anne Merete Aaland ;
Johnson, Egil .
INFLAMMATION, 2005, 29 (4-6) :147-153
[7]   Fungal β-glucans and mammalian immunity [J].
Brown, GD ;
Gordon, S .
IMMUNITY, 2003, 19 (03) :311-315
[8]   Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis [J].
Carneiro, Guilherme ;
Santos, Delia C. M. ;
Oliveira, Monica C. ;
Fernandes, Ana P. ;
Ferreira, Luciana S. ;
Ramaldes, Gilson A. ;
Nunan, Elziria A. ;
Ferreira, Lucas A. M. .
JOURNAL OF LIPOSOME RESEARCH, 2010, 20 (01) :16-23
[9]   Immunohistological features of visceral leishmaniasis in BALB/c mice [J].
Carrión, J ;
Nieto, A ;
Iborra, S ;
Iniesta, V ;
Soto, M ;
Folgueira, C ;
Abanades, DR ;
Requena, JM ;
Alonso, C .
PARASITE IMMUNOLOGY, 2006, 28 (05) :173-183
[10]   Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection [J].
Coelho, EAF ;
Tavares, CAP ;
Carvalho, FAA ;
Chaves, KF ;
Teixeira, KN ;
Rodrigues, RC ;
Charest, H ;
Matlashewski, G ;
Gazzinelli, RT ;
Fernandes, AP .
INFECTION AND IMMUNITY, 2003, 71 (07) :3988-3994